Rigel Pharmaceuticals (RIGL) Receivables - Net (2013 - 2026)

Rigel Pharmaceuticals has reported Receivables - Net for 13 years, with the latest figure at $49.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 1564.83% year-over-year to $49.9 million; the trailing twelve-month figure through Mar 2026 stood at $49.9 million (up 1564.83% YoY), and the FY2025 full-year result was $51.8 million, up 24.39% from the prior year.
• Receivables - Net for Q1 2026 stood at $49.9 million, down from $51.8 million in the prior quarter.
• The five-year high for Receivables - Net was $51.8 million in Q4 2025, with the low at $3.0 million in Q1 2025.
• Average Receivables - Net over 5 years is $28.9 million, with a median of $28.9 million recorded in 2024.
• Year-over-year, Receivables - Net slumped 89.28% in 2022 and jumped 1564.83% in 2026.
• Tracing RIGL's Receivables - Net over 5 years: stood at $20.0 million in 2022, then surged by 52.75% to $30.6 million in 2023, then jumped by 36.22% to $41.6 million in 2024, then increased by 24.39% to $51.8 million in 2025, then declined by 3.51% to $49.9 million in 2026.
• The last three Receivables - Net figures came in at $49.9 million (Q1 2026), $51.8 million (Q4 2025), and $45.9 million (Q3 2025), per Business Quant data.

Peer Comparison